RxDoctor Payments Data

Seema Hisamuddin, MD

Internal Medicine · Marietta, GANPI 1497787998

Payments from drug & device makers

$1,246in general payments, 2019–2025

Across 78 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$362
  • Novo Nordisk$215
  • Astellas Pharma US Inc$138
  • Amgen$126
  • Lilly USA, LLC$58
  • GSK$52
  • plus $295 from 12 others

What the payments were for

  • Food & beverage$1,246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,246 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$232,636
Medicare patients
423
Services billed
5,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$111,031
TrulicityDulaglutide42$47,006
MounjaroTirzepatide25$42,097
EliquisApixaban28$22,443
JardianceEmpagliflozin22$18,377
JanuviaSitagliptin Phosphate12$17,148
SynthroidLevothyroxine Sodium91$9,717
Nebivolol Hcl64$3,872
Clonidine23$3,630
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,177
Estradiol27$3,089
Bupropion XlBupropion Hcl94$2,957
Gabapentin122$2,785
Atorvastatin Calcium336$2,595
Levothyroxine Sodium250$2,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$215$111,03174 claims
Lilly USA, LLCTrulicity, Mounjaro$58$89,10367 claims
PfizerEliquis$39$22,44328 claims
AbbVieSynthroid$362$9,71791 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →